Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy delivered with a multi-directional nebulizer (MDN-PIPAC)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033077

Enrollment

Registered

2023-11-20

Start date

2023-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C48.2

Interventions

Group 1: Retrospective observation of 21 patients with a total of 30 PIPAC applications from a large PIPAC cohort at the Klinikum Dortmund who were treated with PIPAC therapy between 2022 and 2023 due

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who had the chemotherapy drugs administered into the abdominal cavity with the MDN device (multi-directional nebulizer) as part of a PIPAC treatment for peritoneal carcinosis at Klinikum Dortmund between 2022 and 2023.

Exclusion criteria

Exclusion criteria: Patients who objected to retrospective data analysis.

Design outcomes

Primary

Measure	Time frame
Retrospective observation of perioperative mortality after PIPAC applications with the MDN device	—

Secondary

Measure	Time frame
Retrospective observation of morbidity and complications according to Clavien-Dindo after PIPAC applications with the MDN device	—

Countries

Germany

Contacts

Public ContactJürgen Zieren

Klinikum Dortmund

juergen.zieren@klinikumdo.de+49 231 9530

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026